Published in Clin Exp Immunol on February 01, 2012
MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med (2014) 1.51
Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic model. Bioessays (2014) 1.13
MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies. Oncogene (2015) 0.86
Inactivation of MYC reverses tumorigenesis. J Intern Med (2014) 0.84
Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer. Expert Opin Investig Drugs (2013) 0.83
Myc coordinates transcription and translation to enhance transformation and suppress invasiveness. EMBO Rep (2015) 0.82
Elevated neutrophil elastase and acrolein-protein adducts are associated with W256 regression. Clin Exp Immunol (2012) 0.80
Noncanonical roles of the immune system in eliciting oncogene addiction. Curr Opin Immunol (2013) 0.80
Protumoral TSP50 Regulates Macrophage Activities and Polarization via Production of TNF-α and IL-1β, and Activation of the NF-κB Signaling Pathway. PLoS One (2015) 0.79
SGF29 and Sry pathway in hepatocarcinogenesis. World J Biol Chem (2015) 0.77
Kidney transplantation and the ageing immune system. Nat Rev Nephrol (2012) 0.76
Cancer prevention as biomodulation: targeting the initiating stimulus and secondary adaptations. Ann N Y Acad Sci (2012) 0.76
Chemotherapy Resistance Mechanisms in Advanced Skin Cancer. Oncol Rev (2017) 0.75
Broadening the translational immunology landscape. Clin Exp Immunol (2012) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Inflammation and cancer. Nature (2002) 53.78
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Cancer-related inflammation. Nature (2008) 34.21
Inflammation and cancer: back to Virchow? Lancet (2001) 27.40
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science (2002) 17.38
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science (2002) 14.20
Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell (2006) 13.79
Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med (2007) 12.73
Putting tumours in context. Nat Rev Cancer (2001) 12.37
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med (2004) 12.20
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
Paradoxical roles of the immune system during cancer development. Nat Rev Cancer (2006) 10.57
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med (2001) 9.99
Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell (2008) 9.22
The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer (2005) 8.99
CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell (2009) 8.54
Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell (1999) 8.03
MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell (2000) 8.00
Targeted cancer therapy. Nature (2004) 7.81
Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell (2008) 7.65
Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med (1990) 6.87
Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer (2007) 6.58
Essential role for oncogenic Ras in tumour maintenance. Nature (1999) 6.51
The central role of CD4(+) T cells in the antitumor immune response. J Exp Med (1998) 6.02
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell (2005) 5.79
Oncogene addiction. Cancer Res (2008) 5.66
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature (2004) 5.61
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 4.71
TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity (2004) 4.48
Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev (2007) 4.25
Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell (2004) 4.23
Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev (2007) 4.11
The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer (2007) 4.01
FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell (2010) 3.80
Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med (2011) 3.74
Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet (2000) 3.67
The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med (2006) 3.47
Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol (2011) 3.41
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A (2007) 3.37
CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell (2010) 3.33
Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature (1998) 3.22
Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med (2007) 3.11
Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res (2006) 2.84
Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol (2009) 2.84
Pro-senescence therapy for cancer treatment. Nat Rev Cancer (2011) 2.75
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res (2009) 2.51
Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol (2009) 2.31
Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother (2010) 2.30
Endogenous Myc maintains the tumor microenvironment. Genes Dev (2011) 2.16
Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell (2004) 2.08
AIDS-related malignancies. Nat Rev Cancer (2002) 2.03
Natural killer cells and cancer. Adv Cancer Res (2003) 1.99
TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell (2008) 1.91
Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci U S A (2006) 1.89
The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta. Genes Dev (2006) 1.87
The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance. Genes Dev (2010) 1.81
CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci (2003) 1.78
Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci U S A (2005) 1.70
Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev (2009) 1.68
Cancer revoked: oncogenes as therapeutic targets. Nat Rev Cancer (2003) 1.57
Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence. Cancer Cell (2010) 1.53
Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. PLoS One (2008) 1.46
Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. Cancer Res (2007) 1.42
The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia (2010) 1.33
Targeted cancer therapeutics. Cancer Res (2009) 1.30
Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells. Cancer Res (2008) 1.30
The tryptophan-rich motifs of the thrombospondin type 1 repeats bind VLAL motifs in the latent transforming growth factor-beta complex. J Biol Chem (2004) 1.29
Reversibility of oncogene-induced cancer. Curr Opin Genet Dev (2004) 1.27
A dual role for the immune response in a mouse model of inflammation-associated lung cancer. J Clin Invest (2011) 1.25
IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. J Immunol (2001) 1.24
Endogenous thrombospondin-1 is a cell-surface ligand for regulation of integrin-dependent T-lymphocyte adhesion. Blood (2006) 1.17
Characterizing the protective component of the alphabeta T cell response to transplantable squamous cell carcinoma. J Invest Dermatol (2004) 1.11
Oncogenic shock: turning an activated kinase against the tumor cell. Cell Cycle (2006) 0.91
Targeted therapies: peaking beneath the surface of recent bevacizumab trials. Nat Rev Clin Oncol (2011) 0.90
T lymphocyte expression of thrombospondin-1 and adhesion to extracellular matrix components. Eur J Immunol (2002) 0.89
Can antitumor immunity help to explain "oncogene addiction"? Cancer Cell (2010) 0.87
Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody. J Immunother (2010) 0.86
Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer. Cancer Immun (2003) 0.83
c-Myc is a critical target for c/EBPalpha in granulopoiesis. Mol Cell Biol (2001) 2.10
Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas. Leukemia (2011) 1.04
Synthesis of aryl semicarbazones as potential anticonvulsant agents. Biomed Pharmacother (2005) 1.02
STK38 is a critical upstream regulator of MYC's oncogenic activity in human B-cell lymphoma. Oncogene (2012) 0.89
Inactivation of MYC reverses tumorigenesis. J Intern Med (2014) 0.84
SLAC wrist in the absence of recognised trauma and CPPD. Hand Surg (2010) 0.76
Children who harm themselves: development of a paediatric emergency department triage tool. Emerg Med J (2009) 0.76
Intraluminal bowel obstruction by a detached fibroid--an extremely unusual complication of uterine artery embolization. Clin Radiol (2011) 0.75
A novel octamer regulatory element in the VH11 leader exon of B-1 cells. J Immunol (1995) 0.75
c-myc, MHCI, and NK resistance in immunodeficiency lymphomas. Ann N Y Acad Sci (1992) 0.75